Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
Date:2/16/2010

CRANBURY, N.J., Feb. 16 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the fourth quarter and full year 2009.  The Company also provided an update on advancements in its product pipeline related to its key strategic priorities for 2010.  Additionally, the Company stated that it believes it is well positioned to achieve its key milestone of completing enrollment for its Phase 3 study of Amigal™ (migalastat HCl) to support approval in the U.S. (Study 011) by year end.

Fourth Quarter and Full-Year 2009 Financials Summary

Amicus announced net income attributable to common stockholders of $1.45 per share for the three months ended December 31, 2009. For the year ended December 31, 2009, the net loss attributable to common stockholders was $0.29 per share. As of December 31, 2009, cash, cash equivalents, and marketable securities totaled $78.2 million.

John F. Crowley, Chairman and CEO of Amicus Therapeutics stated, "We are very pleased with the significant progress we made advancing Amigal into Phase 3 in 2009, and we expect to continue this momentum in 2010.  We are confident in the likelihood of success for Amigal and are excited we have the potential to bring to market the first oral treatment to patients with Fabry disease."  

Key Strategic Priorities

The Company reaffirmed its three key strategic priorities for 2010: Phase 3 development of migalastat HCl for Fabry disease, advancing chaperone-ERT combina
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013  Flagship Ventures, a leading ... healthcare and sustainability, today announced the appointment of ... Senior Partner. In this role, Mr. Bancel will ... In addition to working closely with ... serves as President and Chief Executive Officer of ...
(Date:5/22/2013)... -- Grifols, a global healthcare company based in ... demonstrating that a higher dose of PROLASTIN © -C ... alpha 1 protein in patients with alpha 1 ... the normal range for healthy individuals. AAT deficiency is ... the alpha 1 proteinase inhibitor (A1PI) protein can ...
(Date:5/22/2013)... , May 22, 2013  Ohr Pharmaceutical Inc. ... of novel therapeutics for unmet medical needs, today announced ... , M.D., Ph.D., to its Board of Directors. Dr. ... on early and late stage drug development. ... Ohr,s Board," said Dr. Irach Taraporewala, CEO of Ohr ...
Breaking Medicine Technology:Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 2Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 3
... 15 ITelagen, Inc., innovative provider of healthcare ... Medical Services, Inc., a leading regional distributor of medical supplies, equipment ... today of the final rule on "meaningful use" of an electronic ... , , ...
... July 15 Merz Aesthetics today announced it is now shipping ... only available in Europe , Asclera™ was recently approved by the ... , , ... Phlebology , leading experts conclude that polidocanol is a highly effective ...
Cached Medicine Technology:Bell Medical and ITelagen Welcome Final Rule for 'Meaningful Use' of Electronic Health Records 2Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 2Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 3Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 4
(Date:5/22/2013)... 22, 2013 A new study published online ... that of young people who visited fast food or chain ... were obese were more likely to use calorie information given ... found that young people eating at fast food or chain ... to use calorie information as those eating there once a ...
(Date:5/22/2013)... 2013 Nearly 50,000 veterans appeals were ... fiscal year 2012, with even more—54,033—expected by fiscal year-end ... a decision as the agency reports reduced decisions and ... veterans disability appeal services. The BVA is an ... Although the BVA received 49,611 cases in FY 2012, ...
(Date:5/22/2013)... People in the United States have been ... shortages. In much of the world, water shortages are normal ... Kleyne. She warns against taking water for granted and provides ... so easily in the United States. , Sharon Kleyne is ... show, heard live or by podcast on World Talk Radio, ...
(Date:5/22/2013)... 2013 According to a May 14, 2013 ... Options for Breast Cancer Surgery,” modern medical technology has given ... this disease in a whole new light. Since the new ... face breast cancer and mastectomies with greater hope ... the introduction of plastic surgery to oncology, women had little ...
(Date:5/22/2013)... (HealthDay News) -- Over the next two decades, the ... expected to more than double, topping more than $180 ... main factor driving the increase: an aging population. The ... American Stroke Association, was published May 22 in the ... the health care system," Dr. Bruce Ovbiagele, chairman of ...
Breaking Medicine News(10 mins):Health News:STRICTLY EMBARGOED UNTIL 6:00AM EST THURSDAY May 23, 2013; Calorie Information in Fast Food Restaurants Used by 40% of 9-18 Year Olds when Making Food Choices, Study Finds 2Health News:STRICTLY EMBARGOED UNTIL 6:00AM EST THURSDAY May 23, 2013; Calorie Information in Fast Food Restaurants Used by 40% of 9-18 Year Olds when Making Food Choices, Study Finds 3Health News:Veterans Disability Appeals See Fewer Decisions in FY2012, Reports Allsup 2Health News:Water Advocate Sharon Kleyne Announces Water Conservation Appreciation 2Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3
... derived from a patient,s own bone marrow were safely used ... results of a Phase I clinical trial at The University ... were published in this month,s issue of Neurosurgery , ... data demonstrate that the acute harvest of bone marrow and ...
... During spring training, you will find Major League pitchers ... muscles to endure the grueling 162 game season. A ... journal of the Association for Psychological Science, suggests that ... could have on their brains. The study, led ...
... THURSDAY, March 10 (HealthDay News) -- New research challenges the ... animal species. It,s long been thought that humans, relatively ... people age more slowly than other animals. Comparisons with short-lived ... idea. But researchers who conducted the first-ever comparison of ...
... 9 (HealthDay News) -- The U.S. Food and Drug Administration on ... than 50 years when it approved Benlysta as a way to ... directly into a vein, Benlysta is the first drug designed to ... cells believed to be at the root of lupus, the FDA ...
... When prostate cancer stem cells (CSCs) were ... SAP stopped cancer stem cell colony formation and also ... (in vitro). According to the international team of researchers ... their results in a recent issue of Cell ...
... Hopkins Children,s Center researchers have discovered that most children ... The newly identified misalignment can affect how surgeries of ... researchers say. The study will be published ... Pediatric Orthopaedics . Previous studies of patients with ...
Cached Medicine News:Health News:Pitchers bean more batters in the heat of the summer 2Health News:Humans Age at Same Pace as Other Primates, Study Finds 2Health News:FDA Approves 1st New Lupus Drug in More Than 50 Years 2Health News:Trapping prostate cancer cells to keep them from spreading provides hope 2Health News:Hopkins Children's study finds some patients with cerebral palsy have asymmetric pelvic bones 2
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
... Ultra thin collagen coated highly ... ultra thin wall construction offers ... The Hemacarotid UltraThin Patch provides ... conformability, and healing, without suture ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
... technology provides a rapid mechanical ... seal that protects and preserves ... plays a role in the ... compromise to the artery or ...
Medicine Products: